SCHEMBL4934170

SCHEMBL4934170

CN1[C@@H]2CC[C@H]1C[C@@H](Oc1cccc(CNC(=O)c3ccc(Oc4ccccc4)cc3)c1)C2

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 6/20 0.56
FFAR1 O14842 1/20 0.55
MMP13 P45452 3/20 0.54
HPGD P15428 1/20 0.54
MAOA P21397 2/20 0.54
OPRK1 P41145 4/20 0.53
HSD17B10 Q99714 1/20 0.51
SLC6A2 P23975 1/20 0.50
SLC6A3 Q01959 1/20 0.50
OPRM1 P35372 3/20 0.49
OPRD1 P41143 3/20 0.49
KCNH2 Q12809 3/20 0.49
LMNA P02545 1/20 0.48
CYP3A4 P08684 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
EPHX2 P34913 1/20 0.48
PPARG P37231 1/20 0.48
PPARA Q07869 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4934168 1.00 MAPK14 (0.56) MAPK14FFAR1MMP13HPGDMAOA
Hydrochloric Acid SCHEMBL4934178 0.99 MAPK14 (0.55) MAPK14FFAR1MMP13HPGDMAOA
Hydrochloric Acid SCHEMBL4934174 0.99 MAPK14 (0.55) MAPK14FFAR1MMP13HPGDMAOA
SCHEMBL14026978 0.92 OPRK1 (0.53) MAPK14FFAR1MAOAOPRK1HSD17B10
SCHEMBL14026962 0.89 OPRK1 (0.54) MMP13HPGDMAOAOPRK1HSD17B10
SCHEMBL4927015 0.89 ROCK2 (0.57) MAPK14MMP13MAOAOPRK1LMNA
SCHEMBL4927011 0.89 ROCK2 (0.57) MAPK14MMP13MAOAOPRK1LMNA
SCHEMBL13911541 0.88 OPRK1 (0.48) MAPK14FFAR1MAOAOPRK1SLC6A2
SCHEMBL4232948 0.88 OPRK1 (0.48) MAPK14FFAR1MAOAOPRK1SLC6A2
SCHEMBL4232946 0.88 OPRK1 (0.48) MAPK14FFAR1MAOAOPRK1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269275-A1 Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders ASTRAZENECA AB (SE) 2008-10-30 US disclosed
US-20080269275-A1 Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders ASTRAZENECA AB (SE) 2008-10-30 US disclosed
US-20080269275-A1 Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders ASTRAZENECA AB (SE) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269275-A1 Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders MCHR1, MCHR2, HCRTR1 MAPK14 2430/4885FFAR1 103/4885MMP13 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.